文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克恢复期血管加压素骤然停用与逐渐减量的比较

Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock.
PubMed 文献 · Shock · 2021-01-01
一句话结论脓毒性休克恢复期骤然停用血管加压素与逐渐减量相比未检出ICU出院时间差异,骤然停用似乎安全且可能缩短用药时长。

这项多中心回顾性队列研究纳入958例(73%)骤然停用和360例(27%)逐渐减量血管加压素的患者,比较脓毒性休克恢复期两种停药方式对结局的影响。主要终点ICU出院时间两组相似:骤然停用组7.9天(95%CI 7.2-8.7天)vs 逐渐减量组7.3天(95%CI 6.3-9.3天,P=0.60);校正基线差异后,逐渐减量并非ICU出院时间的独立预测因素(HR=0.99,95%CI 0.85-1.15,P=0.91)。ICU死亡率(21.8% vs 18.0%,P=0.13)和住院死亡率(28.9% vs 31.1%,P=0.44)无差异,低血压发生率相似(39.7% vs 41.7%,P=0.53),但逐渐减量组更常需要上调血管加压素剂量(5.7% vs 11.1%,P<0.001)。骤然停用组血管加压素中位用药时间更短(1.4天[IQR 0.6-2.6天] vs 1.8天[IQR 1.1-3.2天],P<0.001)。

要点

  • 脓毒性休克恢复期骤然停用血管加压素与逐渐减量相比,ICU出院时间无差异:7.9天(95%CI 7.2-8.7天)vs 7.3天(95%CI 6.3-9.3天,P=0.60)。
  • 校正基线差异后,逐渐减量并非ICU出院时间的独立预测因素(HR=0.99,95%CI 0.85-1.15,P=0.91)。
  • 两组ICU死亡率(21.8% vs 18.0%,P=0.13)和住院死亡率(28.9% vs 31.1%,P=0.44)无差异。
  • 低血压发生率相似(39.7% vs 41.7%,P=0.53),但逐渐减量组更常需要上调血管加压素剂量(5.7% vs 11.1%,P<0.001)。
  • 骤然停用组血管加压素中位用药时间更短(1.4天[IQR 0.6-2.6天] vs 1.8天[IQR 1.1-3.2天],P<0.001)。

适用人群与场景

  • 接受血管加压素联合去甲肾上腺素治疗的脓毒性休克患者,处于休克恢复期(决定滴定或停用血管加压素时)。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入958例(73%)骤然停用血管加压素和360例(27%)逐渐减量患者,两组患者特征和脓毒性休克治疗过程相似。
  • 主要终点ICU出院时间:骤然停用组7.9天(95%CI 7.2-8.7天)vs 逐渐减量组7.3天(95%CI 6.3-9.3天,P=0.60)。
  • 校正基线差异后,逐渐减量并非ICU出院时间的独立预测因素(HR=0.99,95%CI 0.85-1.15,P=0.91)。
  • ICU死亡率:骤然停用组21.8% vs 逐渐减量组18.0%(P=0.13);住院死亡率:28.9% vs 31.1%(P=0.44)。
  • 低血压发生率:骤然停用组39.7% vs 逐渐减量组41.7%(P=0.53);逐渐减量组更常需要上调血管加压素剂量(5.7% vs 11.1%,P<0.001)。
  • 血管加压素中位用药时间:骤然停用组1.4天(IQR 0.6-2.6天)vs 逐渐减量组1.8天(IQR 1.1-3.2天,P<0.001)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒性休克恢复期患者中,骤然停用血管加压素与逐渐减量相比未检出ICU出院时间差异,骤然停用似乎安全,且可能缩短血管加压素用药时长。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To compare patient outcomes based on management of arginine vasopressin (AVP) during the recovery phase of septic shock (abrupt vs. tapering discontinuation).

PATIENTS AND METHODS: Multicenter, retrospective cohort study of patients receiving AVP with concomitant norepinephrine for septic shock. Primary outcome measure was time to intensive care unit (ICU) discharge (from decision to titrate or stop AVP). Secondary outcomes included ICU and hospital mortality, and incidence of hypotension.

RESULTS: A total of 958 (73%) abrupt discontinuation and 360 (27%) down-titration patients were included. Patient characteristics and septic shock treatment courses were similar between groups. Median time to ICU discharge was similar between abrupt discontinuation (7.9 days, 95% CI 7.2-8.7 days) and tapered patients (7.3 days, 95% CI 6.3-9.3 days, P = 0.60). After controlling for baseline discrepancies, down-titration was not an independent predictor of time to ICU discharge (HR = 0.99, 95% CI: 0.85-1.15, P = 0.91). There was no difference in ICU mortality (21.8% vs. 18.0%, P = 0.13) or hospital mortality (28.9% vs. 31.1%, P = 0.44). Although incidence of hypotension was similar (39.7% vs. 41.7%, P = 0.53), patients in the down-titration group more frequently required an escalation of AVP dose (5.7% vs. 11.1%, P < 0.001). Median AVP duration was shorter in the abrupt discontinuation group (1.4 days [IQR: 0.6-2.6 days] vs. 1.8 days [IQR: 1.1-3.2 days], P < 0.001).

CONCLUSIONS: A difference in time to ICU discharge was not detected between abrupt AVP discontinuation and down-titration in patients recovering from septic shock. In patients recovering from septic shock, abrupt discontinuation of AVP appears to be safe and may lead to shortened AVP duration.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Lam SW, Sacha GL, Duggal A, et al. Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock. Shock. 2021. PMID: 32842024. doi:10.1097/SHK.0000000000001609

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。